$LWAC News
Last published 1y ago
- 1y agoLWACLightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment OptionGlobeNewswireDallas, TX, June 26, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the closing
- 1y agoLWACLightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public OfferingGlobeNewswireDallas, TX, June 24, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing
- 5y agoLWACLocust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer TherapiesGlobeNewswireSAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previ
- 5y agoLWACeFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral AgentGlobeNewswireSAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1
- 5y agoLWACeFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell ReportsGlobeNewswireSAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors ("STRIs") for the treatment of cancer, announced today the publication of data highlighting the role of
- 5y agoFMBIFORELEGOLWACMoore Kuehn Encourages FMBI, LWAC, LEGO and FORE Investors to Contact Law FirmPR NewswireNEW YORK, June 21, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shar
- 5y agoLWACeFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical TrialGlobeNewswireSAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient with non-small cell lung ca
- 5y agoLWACLocust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q Stemming from SEC Guidance Concerning Balance Sheet Treatment of WarrantsGlobeNewswireBOSTON, June 03, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) (the "Company"), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that on May 28, 2021 it received a